Position in NVS
as of Jun 30, 2026
· filed Aug 20, 2026
Position Value
$1,410
-$12,643 QoQ
Shares Held
9
-90.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,597
of 1,603 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026GILL CAPITAL PARTNERS, LLC holds $2,047,361 across 12 Drug Manufacturers - General names. NVS ranks #10 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
2,472 | $627,813 | |
| 2 | LLY |
ELI LILLY & Co
|
516 | $618,905 | |
| 3 | ABBV |
AbbVie Inc.
|
1,590 | $400,107 | |
| 4 | AMGN |
Amgen Inc
|
291 | $105,376 | |
| 5 | MRK |
Merck & Co., Inc.
|
766 | $98,431 | |
| 6 | PFE |
Pfizer Inc
|
2,993 | $72,071 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
865 | $49,841 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
338 | $42,702 |
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,410 | 9 | Shares | Sole | 2026-08-20 | |
| 2026-03-31 | $14,053 | 92 | Shares | Sole | 2026-04-13 | |
| No filing history on record for this holder in this stock. | ||||||